ABSTRACT Alzheimer disease (AD) is the leading cause of dementia in older adults and occurs in all ethnic and racial groups. Genetic studies of AD have mostly been performed in non-Hispanic Whites (NHW) of Northern European (NE) ancestry. Only recently have efforts in AD started to expand into other populations, such as African-Americans (AA) and Hispanics (HI), and have a ready demonstrated differences in both risk effect size (e.g., APOE in AA and HI) and risk loci (e.g., ABCA7 in AA). Further evaluation demonstrates that genetic ancestry (as opposed to environmental/cultural factors) likely underlie at least part of this heterogeneity. Individuals with the Amerindian (AI) ancestry remain one of the most underrepresented groups in AD. Importantly, the NHW datasets did not differentiate among the Europeans (EU), whereas recent investigations showed that these pan-European results only partially overlap with the findings from populations from the Iberian Peninsula (IP) with Southern European (SE) ancestry. Caribbean and South American Hispanic populations are admixed with both AI and SE, thus making their study a critical scientific objective. Our proposed study enables testing the generalization of findings from NHW to these other ancestries, as well as identify AD risk/protective factors correlated specifically with AI and SE ancestry. Our results will allow for a better and more complete understanding of the genetic architecture of AD which will help improve disease prediction, prevention, diagnosis, and treatment in AI, admixed Hispanic populations, and beyond. To accomplish these goals, we propose three aims. In Aim 1 we will characterize known AD loci in admixed populations with AI and SE ancestry. This includes expanding collections, generalizing known AD loci to AI/SE populations, and variant discovery through admixture mapping and fine-mapping. In Aim 2 we will extend our Puerto Rican dataset by expanding PR multiplex families. This will allow more powerful linkage analyses, longitudinal neurocognitive and biomarker data, and the initiation of a brain donation program. Finally, in Aim 3 we will perform functional follow-up of variants using bioinformatics approaches, assessment of AD biomarkers, and assessment of cellular function using IPSc.
|Effective start/end date||2/1/21 → 1/31/22|
- National Institute on Aging: $2,330,825.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.